Rutty CJ - Search Results

1

Synthesis and cytotoxicity of potential tumor-inhibitory analogues of trimelamol (2,4,6-tris[(hydroxymethyl)methylamino]-1,3,5-triazine) having electron-withdrawing groups in place of methyl.

Jarman M, Coley HM, Judson IR, Thornton TJ, Wilman DE, Abel G, Rutty CJ. Jarman M, et al. Among authors: rutty cj. J Med Chem. 1993 Dec 24;36(26):4195-200. doi: 10.1021/jm00078a008. J Med Chem. 1993. PMID: 8277501

2

Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).

Judson IR, Calvert AH, Rutty CJ, Abel G, Gumbrell LA, Graham MA, Evans BD, Wilman DE, Ashley SE, Cairnduff F. Judson IR, et al. Among authors: rutty cj. Cancer Res. 1989 Oct 1;49(19):5475-9. Cancer Res. 1989. PMID: 2670205 Clinical Trial.

3

Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Rutty CJ, Judson IR, Abel G, Goddard PM, Newell DR, Harrap KR. Rutty CJ, et al. Cancer Chemother Pharmacol. 1986;17(3):251-8. doi: 10.1007/BF00256694. Cancer Chemother Pharmacol. 1986. PMID: 3091280

4

Low central nervous system penetration of N2,N4,N6,-trihydroxymethyl-N2,N4,N6,-trimethylmelamine (Trimelamol): a cytotoxic s-triazine with reduced neurotoxicity.

Judson IR, Rutty CJ, Abel G, Graham MA. Judson IR, et al. Among authors: rutty cj. Br J Cancer. 1986 May;53(5):601-6. doi: 10.1038/bjc.1986.102. Br J Cancer. 1986. PMID: 3087399 Free PMC article.

5

Metabolism of hexamethylmelamine in mice.

Judson IR, Rutty CJ. Judson IR, et al. Among authors: rutty cj. Cancer Chemother Pharmacol. 1987;20(2):181-2. doi: 10.1007/BF00253977. Cancer Chemother Pharmacol. 1987. PMID: 3117395 No abstract available.

6

In vitro cytotoxicity of the methylmelamines.

Rutty CJ, Abel G. Rutty CJ, et al. Chem Biol Interact. 1980 Feb;29(2):235-46. doi: 10.1016/0009-2797(80)90036-8. Chem Biol Interact. 1980. PMID: 6766359

7

N-methyl antitumour agents. A distinct class of anticancer drugs?

Newell D, Gescher A, Harland S, Ross D, Rutty C. Newell D, et al. Cancer Chemother Pharmacol. 1987;19(2):91-102. doi: 10.1007/BF00254559. Cancer Chemother Pharmacol. 1987. PMID: 3552281 Review.

8

In vivo studies with hexamethylmelamine.

Rutty CJ, Connors TA, Nguyen-Hoang-Nam, Do-Cao-Thang, Hoellinger H. Rutty CJ, et al. Eur J Cancer (1965). 1978 Jun;14(6):713-20. doi: 10.1016/0014-2964(78)90308-0. Eur J Cancer (1965). 1978. PMID: 95953 No abstract available.

9

In vitro studies with hexamethylmelamine.

Rutty CJ, Connors TA. Rutty CJ, et al. Biochem Pharmacol. 1977 Dec 15;26(24):2385-91. doi: 10.1016/0006-2952(77)90446-4. Biochem Pharmacol. 1977. PMID: 413551 No abstract available.

10

The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Rutty CJ, Newell DR, Muindi JR, Harrap KR. Rutty CJ, et al. Cancer Chemother Pharmacol. 1982;8(1):105-11. doi: 10.1007/BF00292880. Cancer Chemother Pharmacol. 1982. PMID: 6807560

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters